BETHLEHEM, PA –  October 22, 2015 – B. Braun Medical Inc., the market leader in regional anesthesia, will launch its latest advancement in echogenic peripheral nerve block needle technology at this year’s American Society of Anesthesiologists (ASA) Annual Meeting at the San Diego Convention Center, Oct. 24-26.

“With our new echogenic X-pattern — designed to provide better echogenicity, 360º visibility, and a more consistent puncture force — the Stimuplex Ultra 360 represents an important advancement in regional anesthesia,” said Brad Lane, Vice President, Critical Care Marketing at B. Braun. “We are committed to improving patient and facility outcomes and we strive to be the customer’s first choice for delivering regional anesthesia safely and effectively.”

Attendees can visit B. Braun’s booth #3523 at ASA to experience hands-on demonstrations of the following products and learn about the company’s regional anesthesia standardization program called B. Braun ONE^sm.       

• Stimuplex Ultra 360 — Experience the echogenicity of B. Braun’s neXt-generation Stimuplex needle. With a new 360º X-pattern, Stimuplex Ultra is designed for better ultrasound visibility from all sides of the needle cannula. Attendees will be among the first to see the ultrasound performance of these needles. Visit www.BBraunUSA.com/SU360 to find out more about Stimuplex Ultra 360.
  
• B-Smart™ Injection Pressure Monitor — Learn more about Injection Safety Monitoring for peripheral nerve block in conjunction with the B-Smart Injection Pressure Monitor. Attendees will gain first-hand experience on a simulator to learn how ultrasound, nerve stimulation, and pressure monitoring can work together to help provide safe and accurate injections. For more information visit www.PNBmonitoring.com.
  
• B. Braun ONE  — Standardize your regional anesthesia products with the market leader in regional anesthesia. Attendees will learn how B. Braun can tailor its standardization program to help them achieve their organization’s goals.

In addition, attendees will learn how they can have their compounded drug needs met through B. Braun’s FDA registered 503B CAPS^® outsourcing facilities. B. Braun also will showcase its needle-free portfolio, Design Options^® customizable IV sets, and ULTRAPORT^TM zero — a swabable auto priming stopcock with zero dead space. 

To learn about B. Braun's activities at ASA, please visit www.bbraunasa.com

About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The Company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. Guided by its “Sharing Expertise^®” philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.

The B. Braun Group of Companies in the U.S. includes B. Braun, B. Braun Interventional Systems, Aesculap^® and CAPS^®. B. Braun’s U.S. headquarters is located in Bethlehem, Pennsylvania. The B. Braun Group of Companies employs more than 54,000 employees in more than 60 countries throughout the world. To learn more about B. Braun visit www.BBraunUSA.com.